Standard medical care of patients with systemic lupus erythematosus (SLE) in large specialised centres: data from the Russian Federation, Ukraine and Republic of Kazakhstan (ESSENCE)
Open Access
- 19 February 2015
- journal article
- research article
- Published by BMJ in Lupus Science & Medicine
- Vol. 2 (1) , e000060
Abstract
Objectives To describe disease characteristics and treatment regimens for adult patients with systemic lupus erythematosus (SLE) with autoantibody positive disease in three countries (the Russian Federation, Ukraine and Republic of Kazakhstan). Methods The ESSENCE study was a 1-year, retrospective, multicentre, observational study. Data included patients’ characteristics, disease activity and severity, and healthcare resource use in 2010. Results Twelve centres enrolled 436 eligible patients: 232 in Russia, 110 in Kazakhstan and 94 in Ukraine. Mean age ranged from 36 to 42 years and median SLE duration from 3 to 6.8 years. According to study definitions, 69.2% of patients in Russia, 72.7% in Kazakhstan and 55.4% in Ukraine had severe disease at diagnosis. SLE activity (Nasonova classification, 1972) decreased from diagnosis to the last visit in 2010 in all countries. At the last visit, mean (SD) Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index score was 13.8 (10.5) in Russia, 19.4 (16.9) in Kazakhstan and 7.2 (6.8) in Ukraine, and Systemic Lupus International Collaborative Clinics/American College of Rheumatology damage index was 2.0 (2.2), 3.3 (3.2) and 2.2 (2.0), respectively. Treatment regimens included predominantly glucocorticoids (96.7–99.1%), immunosuppressants or cytotoxic drugs, for example, azathioprine and cyclophosphamide (20.7–53.2%), and antimalarial drugs (18.3–40.8%). Conclusions The study provides reliable insight into the SLE clinical profiles in the referenced countries. Patients were 4–10 years younger in the study and had 3–7 years shorter SLE duration than in Western European countries and both SLE activity and severity were higher with higher rate of hospitalisations, but decreased during treatment. Local and international scales demonstrated correlation in SLE activity and organ damage evaluation. There were differences in clinical characteristics and healthcare features across the countries.Keywords
This publication has 30 references indexed in Scilit:
- Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort StudyArthritis & Rheumatism, 2013
- Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohortAnnals of the Rheumatic Diseases, 2013
- Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004Arthritis & Rheumatism, 2012
- Systemic lupus erythematosus in an African Caribbean population: Incidence, clinical manifestations, and survival in the Barbados National Lupus RegistryArthritis Care & Research, 2012
- Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohortRheumatology, 2011
- A clinical and epidemiological study of lupus erythematosus at a tertiary referral dermatology clinic in KoreaLupus, 2009
- Direct and Indirect Costs to Employers of Patients With Systemic Lupus Erythematosus With and Without NephritisJournal of Occupational and Environmental Medicine, 2009
- Combined Oral Contraceptives in Women with Systemic Lupus ErythematosusNew England Journal of Medicine, 2005
- Patterns of disease activity in systemic lupus erythematosusArthritis & Rheumatism, 1999
- The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosusArthritis & Rheumatism, 1996